Curr Top Med Chem 5:69–85PubMedCrossRef Mishra R, Ganguly S (2012) Imidazole as an anti-epileptic: an overview. Epilepsy Res 21:3929–3939 Perucca E, French J, Bialer M (2007) Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol 6:793–804PubMedCrossRef Rogawski MA (2006)
Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 69:273–294PubMedCentralPubMedCrossRef Smith M, Wilcox KS, White HS (2007) Discovery of antiepileptic drugs. Neurotherapeutics {Selleck Anti-diabetic Compound Library|Selleck Antidiabetic Compound Library|Selleck Anti-diabetic Compound Library|Selleck Antidiabetic Compound Library|Selleckchem Anti-diabetic Compound Library|Selleckchem Antidiabetic Compound Library|Selleckchem Anti-diabetic Compound Library|Selleckchem Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|buy Anti-diabetic Compound Library|Anti-diabetic Compound Library ic50|Anti-diabetic Compound Library price|Anti-diabetic Compound Library cost|Anti-diabetic Compound Library solubility dmso|Anti-diabetic Compound Library purchase|Anti-diabetic Compound Library manufacturer|Anti-diabetic Compound Library research buy|Anti-diabetic Compound Library order|Anti-diabetic Compound Library mouse|Anti-diabetic Compound Library chemical structure|Anti-diabetic Compound Library mw|Anti-diabetic Compound Library molecular weight|Anti-diabetic Compound Library datasheet|Anti-diabetic Compound Library supplier|Anti-diabetic Compound Library in vitro|Anti-diabetic Compound Library cell line|Anti-diabetic Compound Library concentration|Anti-diabetic Compound Library nmr|Anti-diabetic Compound Library in vivo|Anti-diabetic Compound Library clinical trial|Anti-diabetic Compound Library cell assay|Anti-diabetic Compound Library screening|Anti-diabetic Compound Library high throughput|buy Antidiabetic Compound Library|Antidiabetic Compound Library ic50|Antidiabetic Compound Library price|Antidiabetic Compound Library cost|Antidiabetic Compound Library solubility dmso|Antidiabetic Compound Library purchase|Antidiabetic Compound Library manufacturer|Antidiabetic Compound Library research buy|Antidiabetic Compound Library order|Antidiabetic Compound Library chemical structure|Antidiabetic Compound Library datasheet|Antidiabetic Compound Library supplier|Antidiabetic Compound Library in vitro|Antidiabetic Compound Library cell line|Antidiabetic Compound Library concentration|Antidiabetic Compound Library clinical trial|Antidiabetic Compound Library cell assay|Antidiabetic Compound Library screening|Antidiabetic Compound Library high throughput|Anti-diabetic Compound high throughput screening| 4:12–17PubMedCrossRef White HS, Woodhead JH, Wilcox KS, Stables JP, Kupferberg HJ, Wolf HH (2002) General principles: discovery and preclinical development of find more antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS, Perucca E (eds) Antiepileptic drugs, 5th edn.
Lippincott Williams and Wilkins Publishers, New York, pp 6–48″
“Introduction Nonsteroidal anti-inflammatory drugs (NSAIDs) are most widely used to treat variety of acute and chronic inflammatory diseases. Such drugs are being increasingly used for the treatment of postoperative pain (Moote, 1992) with or without supplemental opioid agents. The pharmacological action of these agents was assigned to inhibit two enzymes, known as cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) (Vane et al., 1998). The constitutive isoform COX-1 is present in most tissues and is involved in the synthesis of prostaglandins vital to normal cell function. In contrast, the inducible isoform COX-2 appears to be produced primarily in response to growth factors or inflammatory mediators, such as cytokines (Vane and Botting, 1996). Many of the currently available NSAIDs, including indomethacin and piroxicam, are more potent inhibitors of COX-1 than that of COX-2 (Vane and Botting, 1995). This preferential inhibition of COX-1 may be responsible for many of
the adverse effects associated with NSAIDs. It has been postulated that NSAIDs which preferentially many inhibit COX-2, such as meloxicam (Lipscomb et al., 1998), celecoxib (Simon et al., 1998) and several experimental drugs including NS 398, L-745,337 and DFP, CX-5461 cost should produce the same or better anti inflammatory effects with less gastrointestinal, haematological and renal toxicities than classical NSAIDs (Winter et al., 1962). Pyrazolopyrimidines are a class of sedative and anxiolytic drugs such as Zaleplon known by its hypnotic effect (Weitzel et al., 2000). However, pyrazolopyrimidine derivatives become a new chemical resource for searching of novel bioactive compounds in drug development.